Varian Biopharmaceuticals, a biopharmaceutical company, agreed to go public via a SPAC merger with SPK Acquisition, a special purposes acquisition company, in a $116m. “Varian Bio has the support of leading cancer physicians and scientific institutions both in the US and abroad, and aPKCi is a unique protein kinase target whose inhibition could have a significant impact in a broad range of tumor types. Our merger with SPK will provide the capital needed to further the development of our proprietary, anti-cancer targeted therapies," Jeffrey B. Davis, Varian Bio CEO.